AVITA Medical (RCEL) Cost of Revenue (2018 - 2025)

AVITA Medical's Cost of Revenue history runs 8 years deep, the most recent figure standing at $3.3 million for Q4 2025.

• Quarterly Cost of Revenue rose 44.91% year-over-year to $3.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $12.8 million (up 40.68% YoY) and the FY2025 annual result came in at $12.8 million, up 40.69% from the prior year.
• Cost of Revenue was $3.3 million for Q4 2025 at AVITA Medical, up from $3.2 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $5.3 million in Q3 2021 and bottomed at $1.5 million in Q1 2024.
• A 5-year average of $2.6 million and a median of $2.2 million in 2021 frame the typical range for Cost of Revenue.
• Annual changes were most pronounced in 2021 — Cost of Revenue surged 469.11% — and 2022, when it plunged 71.06%.
• AVITA Medical's Cost of Revenue stood at $5.3 million in 2021, then tumbled by 60.73% to $2.1 million in 2022, then retreated by 13.49% to $1.8 million in 2023, then gained by 26.95% to $2.3 million in 2024, then surged by 44.91% to $3.3 million in 2025.
• Business Quant data shows RCEL's Cost of Revenue at $3.3 million in Q4 2025, $3.2 million in Q3 2025, and $3.5 million in Q2 2025.